← All trials
NCT04765995
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2021
- Primary completion
- Oct 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Feb 23, 2021
- Last posted
- Mar 1, 2021
- Enrollment
- 40
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hangzhou Grand Biologic Pharmaceutical, Inc.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Chinese Academy of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.